Page last updated: 2024-11-10

n-desmethylvenlafaxine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

N-desmethylvenlafaxine: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

N-desmethylvenlafaxine : A monomethoxybenzene that is the N-desmethyl derivative of venlafaxine. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID3501942
CHEMBL ID1119
CHEMBL ID1628258
CHEBI ID83525
SCHEMBL ID734652
MeSH IDM0397707

Synonyms (38)

Synonym
chebi:83525 ,
n-desmethylvenlafaxine
CHEMBL1119
1-[1-(4-methoxyphenyl)-2-(methylamino)ethyl]cyclohexan-1-ol
FT-0666244
CHEMBL1628258 ,
bdbm50367952
n-desmethyl venlafaxine
unii-19v5ex4e8b
19v5ex4e8b ,
149289-30-5
1-[1-(4-methoxyphenyl)-2-(methylamino)ethyl]cyclohexanol
norvenlafaxine
rac n-desmethyl venlafaxine
venlafaxine hydrochloride impurity d [ep impurity]
1-((1rs)-1-(4-methoxyphenyl)-2-(methylamino)ethyl)cyclohexanol
cyclohexanol, 1-(1-(4-methoxyphenyl)-2-(methylamino)ethyl)-
d,l n-desmethyl venlafaxine
SCHEMBL734652
MKAFOJAJJMUXLW-UHFFFAOYSA-N
AKOS027326324
J-008575
nve_264.1959_12.6
n-desvenlafaxine
d,l n-desmethylvenlafaxine
Q27156915
mfcd04039502
BCP33876
SB33767
1-(1-(4-methoxyphenyl)-2-(methylamino)ethyl)cyclohexanol
DTXSID20881050
CS-0340202
n-desmethyl venlafaxin
cyclohexanol, 1-[1-(4-methoxyphenyl)-2-(methylamino)ethyl]-
EN300-26487202
1-[1-(4-methoxy-phenyl)-2-methylamino-ethyl]-cyclohexanol
venlafaxine-n-desmethyl
cyclohexanol, 1-[1-(4-methoxyphenyl)-2-(methylamino)ethyl]-; 1-[1-(4-methoxyphenyl)-2-(methylamino)ethyl]cyclohexanol; n-desmethylvenlafaxine; norvenlafaxine

Research Excerpts

Compound-Compound Interactions

ExcerptReferenceRelevance
" In conclusion, the high suicide potential of VEN in combination with the high prevalence of drugs causing adverse interactions could be the reason for the observed high FTI."( Fatal venlafaxine poisonings are associated with a high prevalence of drug interactions.
Launiainen, T; Ojanperä, I; Rasanen, I; Vuori, E, 2011
)
0.37
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
marine xenobiotic metaboliteAny metabolite produced by metabolism of a xenobiotic compound in marine macro- and microorganisms.
drug metabolitenull
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
cyclohexanolsAn alcohol in which one or more hydroxy groups are attached to a cyclohexane skeleton.
monomethoxybenzeneCompounds containing a benzene skeleton substituted with one methoxy group.
secondary amino compoundA compound formally derived from ammonia by replacing two hydrogen atoms by organyl groups.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
Venlafaxine Metabolism Pathway612

Bioassays (21)

Assay IDTitleYearJournalArticle
AID681144TP_TRANSPORTER: cell accumulation of calcein in L-MDR1 cells2003The Journal of pharmacology and experimental therapeutics, Apr, Volume: 305, Issue:1
Inhibition of P-glycoprotein by newer antidepressants.
AID1210239Total brain to plasma partition coefficient of the compound in mdr1a-deficient rat treated with venlafaxine at 9 mg/kg/day administered through continuous minipump treatment for 3 days2012Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 40, Issue:3
Species comparison of in vivo P-glycoprotein-mediated brain efflux using mdr1a-deficient rats and mice.
AID1210181Unbound brain to plasma partition coefficient of the compound in wild type Crl:CF1 mouse expressing Abcb1a mutant treated with venlafaxine at 12 mg/kg/day administered through continuous minipump treatment for 3 days2012Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 40, Issue:3
Species comparison of in vivo P-glycoprotein-mediated brain efflux using mdr1a-deficient rats and mice.
AID1210187Total brain to plasma partition coefficient of the compound in wild type Crl:CF1 mouse expressing Abcb1a mutant treated with venlafaxine at 12 mg/kg/day administered through continuous minipump treatment for 3 days2012Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 40, Issue:3
Species comparison of in vivo P-glycoprotein-mediated brain efflux using mdr1a-deficient rats and mice.
AID1210218Percentage unbound in Crl:NMRI(Han) mouse plasma at 1 uM after 5 hrs by equilibrium dialysis method2012Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 40, Issue:3
Species comparison of in vivo P-glycoprotein-mediated brain efflux using mdr1a-deficient rats and mice.
AID1210222Total plasma concentration in wild type Sprague-Dawley rat expressing Abcb1a treated with venlafaxine at 9 mg/kg/day administered through continuous minipump treatment for 3 days by UPLC-MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 40, Issue:3
Species comparison of in vivo P-glycoprotein-mediated brain efflux using mdr1a-deficient rats and mice.
AID1210169Unbound brain to plasma partition coefficient of the compound in wild type Sprague-Dawley rat expressing Abcb1a treated with venlafaxine at 9 mg/kg/day administered through continuous minipump treatment for 3 days2012Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 40, Issue:3
Species comparison of in vivo P-glycoprotein-mediated brain efflux using mdr1a-deficient rats and mice.
AID1210238Total drug level in mdr1a-deficient rat brain treated with venlafaxine at 9 mg/kg/day administered through continuous minipump treatment for 3 days by UPLC-MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 40, Issue:3
Species comparison of in vivo P-glycoprotein-mediated brain efflux using mdr1a-deficient rats and mice.
AID1210203Total plasma concentration in mdr1a-deficient mouse treated with venlafaxine at 12 mg/kg/day administered through continuous minipump treatment for 3 days by UPLC-MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 40, Issue:3
Species comparison of in vivo P-glycoprotein-mediated brain efflux using mdr1a-deficient rats and mice.
AID1210186Total drug level in wild type Crl:CF1 mouse brain expressing Abcb1a mutant treated with venlafaxine at 12 mg/kg/day administered through continuous minipump treatment for 3 days by UPLC-MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 40, Issue:3
Species comparison of in vivo P-glycoprotein-mediated brain efflux using mdr1a-deficient rats and mice.
AID1210216Percentage unbound in Sprague-Dawley rat brain at 1 uM after 5 hrs by equilibrium dialysis method2012Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 40, Issue:3
Species comparison of in vivo P-glycoprotein-mediated brain efflux using mdr1a-deficient rats and mice.
AID1210215Percentage unbound in Sprague-Dawley rat plasma at 1 uM after 5 hrs by equilibrium dialysis method2012Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 40, Issue:3
Species comparison of in vivo P-glycoprotein-mediated brain efflux using mdr1a-deficient rats and mice.
AID1210204Total drug level in mdr1a-deficient mouse brain treated with venlafaxine at 12 mg/kg/day administered through continuous minipump treatment for 3 days by UPLC-MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 40, Issue:3
Species comparison of in vivo P-glycoprotein-mediated brain efflux using mdr1a-deficient rats and mice.
AID1210223Total drug level in wild type Sprague-Dawley rat brain expressing Abcb1a treated with venlafaxine at 9 mg/kg/day administered through continuous minipump treatment for 3 days by UPLC-MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 40, Issue:3
Species comparison of in vivo P-glycoprotein-mediated brain efflux using mdr1a-deficient rats and mice.
AID1210174Unbound brain to plasma partition coefficient of the compound in mdr1a-deficient Sprague-Dawley rat treated with venlafaxine at 9 mg/kg/day administered through continuous minipump treatment for 3 days2012Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 40, Issue:3
Species comparison of in vivo P-glycoprotein-mediated brain efflux using mdr1a-deficient rats and mice.
AID1210205Total brain to plasma partition coefficient of the compound in mdr1a-deficient mouse treated with venlafaxine at 12 mg/kg/day administered through continuous minipump treatment for 3 days2012Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 40, Issue:3
Species comparison of in vivo P-glycoprotein-mediated brain efflux using mdr1a-deficient rats and mice.
AID1210178Percentage unbound in Crl:NMRI(Han) mouse brain at 1 uM after 5 hrs by equilibrium dialysis method2012Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 40, Issue:3
Species comparison of in vivo P-glycoprotein-mediated brain efflux using mdr1a-deficient rats and mice.
AID1210185Total plasma concentration in wild type Crl:CF1 mouse expressing Abcb1a mutant treated with venlafaxine at 12 mg/kg/day administered through continuous minipump treatment for 3 days by UPLC-MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 40, Issue:3
Species comparison of in vivo P-glycoprotein-mediated brain efflux using mdr1a-deficient rats and mice.
AID1210224Total brain to plasma partition coefficient of the compound in wild type Sprague-Dawley rat expressing Abcb1a treated with venlafaxine at 9 mg/kg/day administered through continuous minipump treatment for 3 days2012Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 40, Issue:3
Species comparison of in vivo P-glycoprotein-mediated brain efflux using mdr1a-deficient rats and mice.
AID1210164Unbound brain to plasma partition coefficient of the compound in mdr1a-deficient mouse treated with venlafaxine at 12 mg/kg/day administered through continuous minipump treatment for 3 days2012Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 40, Issue:3
Species comparison of in vivo P-glycoprotein-mediated brain efflux using mdr1a-deficient rats and mice.
AID1210237Total plasma concentration in mdr1a-deficient rat treated with venlafaxine at 9 mg/kg/day administered through continuous minipump treatment for 3 days by UPLC-MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 40, Issue:3
Species comparison of in vivo P-glycoprotein-mediated brain efflux using mdr1a-deficient rats and mice.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (14)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's4 (28.57)29.6817
2010's9 (64.29)24.3611
2020's1 (7.14)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.98

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.98 (24.57)
Research Supply Index2.71 (2.92)
Research Growth Index4.69 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.98)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (7.14%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other13 (92.86%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]